Stanley Capital
Stanley Capital Partners is a European mid-market private equity firm using a research and technology-based approach to identify opportunities in the growing sustainable investment sectors of Healthcare and Resource Efficiency. Stanley Capital targets businesses with the potential of generating EBITDA of $25m to $150m. We partner with management teams, in majority and minority transactions, to transform and grow companies through technological change, operational change and market consolidation. Stanley Capital was founded in 2019 by Simon Cottle, James Brooks and Patrick Hargutt and has a team of over 100 professionals working closely together with its Leader Network and investors, sector and technology partners.
Company Overview
Stanley Capital operates in the Investment Management industry, focusing on mid-market private equity investments. The firm is based in London, GB, and employs a team of 23 professionals. Established in 2019, Stanley Capital emphasizes a digital-first approach to investment, aiming to unlock potential in growth businesses. The company targets enterprises with EBITDA ranging from $25 million to $150 million and enterprise values between $250 million and $2.5 billion.
Investment Focus
Stanley Capital specializes in sustainable investment sectors, particularly in Healthcare and Resource Efficiency. The firm employs a research and technology-based strategy to identify investment opportunities. It partners with management teams for both majority and minority transactions, focusing on driving technological and operational changes within its portfolio companies. The firm has a proven track record of generating significant returns, including a 6.7x return on the investment in Noden Pharma.
Founders
Stanley Capital was founded by Simon Cottle, James Brooks, and Patrick Hargutt in 2019. The founders bring extensive experience in investment management and have established a firm that leverages technology and research to enhance investment strategies. Their leadership guides the company's focus on sustainable investments and partnerships with growth-oriented businesses.
Recent Initiatives
Stanley Capital has announced several key initiatives, including its first Resource Efficiency Investment with Roboyo and backing Laboratoire X.O in acquiring an anaesthetic prescription product. The firm has also formed strategic partnerships, such as with Applied Artificial Intelligence Corporation, to integrate AI into private equity investments. Additionally, the launch of SCP Digital aims to enhance the company's digital capabilities in investment management.
Partnerships and Collaborations
Stanley Capital collaborates with various partners to maximize investment potential. The firm has partnered with Grafine Partners to invest in sustainable businesses and has backed several portfolio companies in strategic acquisitions. Notable partnerships include backing Qinecsa in acquiring Commonwealth Informatics and Drug Safety Solutions in acquiring My Meds and Me. These collaborations reflect Stanley Capital's commitment to driving growth and innovation in its investment strategies.